What is HC Wainwright’s Estimate for Verastem Q1 Earnings?

Verastem, Inc. (NASDAQ:VSTM) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Verastem in a research report issued on Monday, March 24th. HC Wainwright analyst S. Lee expects that the biopharmaceutical company will post earnings of ($0.67) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.10) EPS and FY2027 earnings at ($0.33) EPS.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.57).

Other research analysts have also issued research reports about the company. Royal Bank of Canada dropped their price target on Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, March 21st. BTIG Research lifted their target price on Verastem from $13.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Guggenheim increased their price target on Verastem from $13.00 to $14.00 and gave the company a “buy” rating in a report on Monday. StockNews.com raised shares of Verastem from a “sell” rating to a “hold” rating in a research note on Monday. Finally, B. Riley increased their target price on shares of Verastem from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.88.

Verastem Price Performance

Verastem stock opened at $6.40 on Thursday. Verastem has a 52-week low of $2.10 and a 52-week high of $13.52. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. The firm’s fifty day moving average is $6.10 and its 200 day moving average is $4.72. The company has a market cap of $284.84 million, a price-to-earnings ratio of -2.01 and a beta of 0.60.

Institutional Investors Weigh In On Verastem

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its position in shares of Verastem by 46.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 103,601 shares of the biopharmaceutical company’s stock worth $310,000 after acquiring an additional 32,791 shares during the period. FMR LLC bought a new position in Verastem in the third quarter worth approximately $41,000. Stonepine Capital Management LLC purchased a new position in Verastem during the 3rd quarter worth $3,918,000. Walleye Capital LLC raised its position in Verastem by 493.7% during the 3rd quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 179,725 shares in the last quarter. Finally, Stifel Financial Corp lifted its holdings in shares of Verastem by 62.3% in the 3rd quarter. Stifel Financial Corp now owns 30,339 shares of the biopharmaceutical company’s stock worth $91,000 after buying an additional 11,642 shares during the period. 88.37% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Verastem

In related news, CEO Dan Paterson sold 8,568 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $5.24, for a total value of $44,896.32. Following the transaction, the chief executive officer now owns 347,581 shares of the company’s stock, valued at $1,821,324.44. This trade represents a 2.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 9,960 shares of company stock worth $53,498. 2.20% of the stock is currently owned by insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.